Oyster Point Pharma
40°40′43″N 78°14′35″W / 40.678631°N 78.243038°W
| Company type | Public company |
|---|---|
| Nasdaq: OYST | |
| Industry | Biotechnology |
| Founded | 2015[1] |
| Headquarters | , U.S. |
Key people | Jeffrey Nau (President and CEO) |
| Website | www |
Oyster Point Pharma, Inc. is an American biopharmaceutical based in Princeton, New Jersey, focusing on the development of pharmaceutical therapies to treat ophthalmic diseases.[2]
Products
The lead product of the company is Tyrvaya. In October 2021, it was the first nasal spray approved by Food and Drug Administration to treat dry eye syndrome.[3]
Initial public offering and stock history
Prior to going public, Oyster Point Pharma operated at a loss of $16.5 million in 2018.[4] In February 2019, still at clinical stage, the company raised $93 million in its Series B funding round.[5][6]
In October 2019, the company issued 5-million shares in the initial public offering with NASDAQ Global Select Market at the price of $16 per share with the first trading day on October 31.[7]
References
- ^ "SEC FORM S-1". Oyster Point Pharma. Retrieved 27 April 2022.
- ^ "Oyster Point Pharma Inc". Reuters. Retrieved 27 April 2022.
- ^ Harrison, Laird (27 October 2021). "FDA Approves First Nasal Spray for Dry Eye". WenMD Health News. Retrieved 27 April 2022.
- ^ Marinova, Polina (31 October 2019). "Fair's CEO Scott Painter Resigns as Car-Leasing Startup Seeks a Path to Profitability". Fortune. Retrieved 27 April 2022.
- ^ Marinova, Polina (26 February 2019). "Term Sheet — Tuesday, February 26". Fortune. Retrieved 27 April 2022.
- ^ Gormley, Brian (26 February 2019). "Oyster Point Pharma Banks $93 Million for Dry Eye Therapy". Wall Street Journal Pro. Retrieved 27 April 2022.
- ^ Vecchione, Anthony (31 October 2019). "Oyster Point Pharma shares gain in IPO". NJBIZ. Retrieved 27 April 2022.